Joao Agostinho Machado-Neto
Overview
Explore the profile of Joao Agostinho Machado-Neto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alcantara G, do Nascimento M, de Miranda L, de Almeida B, Lima K, Rego E, et al.
Pharmacol Rep
. 2025 Mar;
PMID: 40056292
Background: Gliomas, particularly glioblastomas, are highly aggressive cancers with rapid proliferation and poor prognosis. Current treatments have limited efficacy, highlighting the need for new therapeutic strategies. Eribulin mesylate, a synthetic...
2.
Parducci N, Garnique A, de Almeida B, Machado-Neto J
Gene
. 2025 Mar;
950:149365.
PMID: 40024298
The intricate molecular mechanisms associated with cancer development continue to engage researchers due to the significant impact of the disease on global mortality. This review delves into the role of...
3.
Machado-Neto J, Vicari H, Lipreri da Silva J, Carvalho M, Lima K
Transl Cancer Res
. 2024 Dec;
13(11):6105-6116.
PMID: 39697714
Background: Myeloid neoplasms encompass disorders characterized by abnormal myeloid cell proliferation and differentiation, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms, acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). Formin-like protein...
4.
Zhao J, Cui Y, Zhou H, Zhou D, Che Z, Zhang N, et al.
Transl Cancer Res
. 2024 Dec;
13(11):6255-6272.
PMID: 39697705
Background: The use of FMS-like tyrosine kinase 3 () as a crucial target for kinase inhibitors is well established, but its association with immune infiltration remains unclear. This study aimed...
5.
Lima K, Rojas C, Nogueira F, Silva W, Cavaglieri R, Nardinelli L, et al.
EJHaem
. 2024 Dec;
5(6):1366-1369.
PMID: 39691248
No abstract available.
6.
Sanchez-Mendoza S, de Deus-Wagatsuma V, do Nascimento M, Lima K, Machado-Neto J, Djavaheri-Mergny M, et al.
Ann Hematol
. 2024 Dec;
103(12):5405-5416.
PMID: 39661129
Acute myeloid leukemia (AML) with FLT3-ITD mutation represents a quarter of AML patients and is associated with high relapse rate and dismal prognosis. FLT3 tyrosine kinase inhibitors (TKIs) were developed...
7.
Lipreri da Silva J, Lima K, Ede B, Lazarini M, Vicari H, Nogueira F, et al.
Eur J Pharmacol
. 2024 Nov;
987:177161.
PMID: 39615869
Ezrin (EZR) is an actin-associated protein that is often upregulated in cancers. Here we investigate the role of EZR in acute lymphoblastic leukemia (ALL) and explore the therapeutic potential of...
8.
Santos de Macedo B, Albuquerque de Melo M, Pereira-Martins D, Machado-Neto J, Traina F
Biochim Biophys Acta Rev Cancer
. 2024 Nov;
1879(6):189214.
PMID: 39515545
The gradual acquisition of genetic and epigenetic disturbances bestows malignant traits upon hematopoietic stem cells, subverting them into a founder and reservoir cell for de novo acute myeloid leukemia (AML)...
9.
Santos de Macedo B, Albuquerque de Melo M, Pereira-Martins D, Machado-Neto J, Traina F
Sci Rep
. 2024 Oct;
14(1):23882.
PMID: 39396074
Beyond its clinical diversity and severity, acute myeloid leukemia (AML) is known for its complex molecular background and for rewiring biological processes to aid disease onset and maintenance. FLT3 mutations...
10.
Carlos J, Lima K, Rego E, Costa-Lotufo L, Machado-Neto J
Hematol Transfus Cell Ther
. 2024 Sep;
46 Suppl 6:S217-S227.
PMID: 39261151
The central role of the control of apoptosis in the pathophysiology of Philadelphia chromosome-negative myeloproliferative neoplasms has recently been reinforced in genetic and pharmacological studies. The inhibitor of apoptosis protein...